Revance Therapeutics Inc (NASDAQ: RVNC) on Monday, soared 12.30% from the previous trading day, before settling in for the closing price of $3.09. Within the past 52 weeks, RVNC’s price has moved between $2.30 and $8.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 1041.31%. The company achieved an average annual earnings per share of 42.40%. With a float of $95.30 million, this company’s outstanding shares have now reached $104.90 million.
The extent of productivity of a business whose workforce counts for 597 workers is very important to gauge. In terms of profitability, gross margin is 70.66%, operating margin of -67.21%, and the pretax margin is -72.59%.
Revance Therapeutics Inc (RVNC) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Revance Therapeutics Inc is 8.71%, while institutional ownership is 80.80%. The most recent insider transaction that took place on Nov 18 ’24, was worth 16,296. In this transaction CMO & Global Therapeutics Lead of this company sold 3,908 shares at a rate of $4.17, taking the stock ownership to the 104,945 shares. Before that another transaction happened on Apr 16 ’24, when Company’s Chief Commercial Officer sold 2,392 for $3.80, making the entire transaction worth $9,096. This insider now owns 114,864 shares in total.
Revance Therapeutics Inc (RVNC) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 42.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.60% during the next five years compared to 0.57% growth over the previous five years of trading.
Revance Therapeutics Inc (NASDAQ: RVNC) Trading Performance Indicators
Revance Therapeutics Inc (RVNC) is currently performing well based on its current performance indicators. A quick ratio of 3.05 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.92, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Revance Therapeutics Inc (RVNC)
The latest stats from [Revance Therapeutics Inc, RVNC] show that its last 5-days average volume of 4.07 million was inferior to 5.86 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 75.12%. Additionally, its Average True Range was 0.15.
During the past 100 days, Revance Therapeutics Inc’s (RVNC) raw stochastic average was set at 12.64%, which indicates a significant decrease from 75.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.71% in the past 14 days, which was lower than the 102.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.98, while its 200-day Moving Average is $4.25. Now, the first resistance to watch is $3.57. This is followed by the second major resistance level at $3.66. The third major resistance level sits at $3.72. If the price goes on to break the first support level at $3.42, it is likely to go to the next support level at $3.36. The third support level lies at $3.27 if the price breaches the second support level.
Revance Therapeutics Inc (NASDAQ: RVNC) Key Stats
Market capitalization of the company is 365.78 million based on 104,390K outstanding shares. Right now, sales total 234,040 K and income totals -323,990 K. The company made 59,880 K in profit during its latest quarter, and -38,120 K in sales during its previous quarter.
